RFL | tickerfilter.com

Fundamental analysis

27%

Profitability 0%

Dept financing 30%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.76%

1 Month

20.16%

3 Months

-3.87%

6 Months

3.47%

1 Year

-17.22%

2 Year

-11.31%

Key data

Stock price

$1.49

P/E Ratio

0.00

DAY RANGE

$1.43 - $1.55

EPS

-$0.86

52 WEEK RANGE

$1.12 - $3.19

52 WEEK CHANGE

-$17.22

MARKET CAP

69.611 M

YIELD

1.38%

SHARES OUTSTANDING

51.763 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

06-13-2025

BETA

0.39

PUBLIC FLOAT

AVERAGE 10 VOLUME

$174,694

AVERAGE 30 VOLUME

$92,879

Company detail

CEO: William Conkling
Region: US
Website: www.rafaelholdings.com
Employees: 20
IPO year: 2018

Issue type: Common Stock
Market: NYSE
Industry: Real Estate/Real Estate
Sector: Finance, Insurance, And Real Estate

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies and commercial real estate assets. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.

RFL - Rafael Holdings, Inc.